Anixa Biosciences presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek, its artificial intelligence driven cancer detection technology, at the American Association of Cancer Research Special Conference on Tumor Immunology and Immunotherapy. Anixa presented data demonstrating the ability of Cchek to identify the presence of early stage breast cancer in a subject by using its AI technology to analyze a simple blood draw. The Cchek technology demonstrated a sensitivity of 89.3% when detecting early stage breast cancer (Stage I or II) and a specificity (the ability to correctly identify healthy subjects) of 94.7% when used to test blinded samples. Furthermore, Cchek was also able to detect the early stages of breast cancer (Stage 0) in subjects with biopsy-confirmed ductal carcinoma in situ, a type of pre-cancerous/non-invasive breast lesion that often leads to invasive breast cancer, with 72% sensitivity.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.